Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Malaria & NTDs R&D Investment by Year
Malaria & NTDs R&D Investment ($M)
Novartis Malaria & NTDs R&D Investment: $142M in FY2025, up 6.8% from a year earlier.
Latest, FY2025
142
Period ended Dec 31, 2025
Change on a year earlier
+6.8%
133 in FY2024
History
5 years
Since FY2021
Sources
2
Documents cited below
Where the FY2025 figure comes from
“| Investment in R&D for malaria and neglected tropical diseases (NTDs) (USD millions) | 142 | 133 | ”
Source: Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗
Reported in ESG Data Summary 2025.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Malaria & NTDs R&D Investment ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 142 | +6.8% | Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗ |
| FY2024 | Dec 31, 2024 | 133 | +35.2% | Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗ |
| FY2023 | Dec 31, 2023 | 98.4 | +27.5% | Novartis Form 6-K (0001370368-24-000008) ↗ |
| FY2022 | Dec 31, 2022 | 77.2 | +49.9% | Novartis Form 6-K (0001370368-24-000008) ↗ |
| FY2021 | Dec 31, 2021 | 51.5 | – | Novartis Form 6-K (0001370368-24-000008) ↗ |
Cite this data
StockData. (2026). Novartis Malaria & NTDs R&D Investment ($M), annual FY2021–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/access-malaria-ntd-rd-m
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.